Company intelligence / Profile preview

Latticon Antibody Therapeutics, Inc.

Gaithersburg, Maryland, United States

Ownership: Private
Development stage: Other

Overview

LAT010—Latticon’s lead program—is a first-in-human immunocytokine targeting IL‑2Rβγ. It received FDA IND approval in late 2023 and entered a Phase 1/2 open-label multicenter trial in June 2024 for advanced solid tumors. The study evaluates safety/tolerability and preliminary efficacy; as of early 2025 the trial remains ongoing with no published results yet

Therapeutic areas: Oncology
Modalities: Immunocytokines (human IL-2 based antibody fusion proteins)
Industry: Biotech

Drug pipeline

1 asset

LAT010

Partnerships

Zencore Biologics provided CMC/CDMO services for LAT010 development and IND submission support

Beyond the preview

Go deeper on Latticon Antibody Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latticon Antibody Therapeutics, Inc..